

### Basic science (November 2005)

1. Agarwal B, Saxena R, Morimiya A, Mehrotra S, Badve S. Lymphangiogenesis does not occur in breast cancer. *Am J Surg Pathol* 2005; **29**: 1449–1455.
2. Ahn J, Gammon MD, Santella RM, Gaudet MM, Britton JA, Teitelbaum SL, Terry MB, Nowell S, Davis W, Garza C, Neugut AI, Ambrosone CB. Associations between breast cancer risk and the catalase genotype, fruit and vegetable consumption, and supplement use. *Am J Epidemiol* 2005; **162**: 943–952.
3. Benlimame N, He Q, Jie S, Xiao DZ, Xu YJ, Loignon M, Schlaepfer DD, Alaoui-Jamali MA. FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion. *J Cell Biol* 2005; **171**: 505–516.
4. Berglund P, Stighall M, Jirstrom K, Borgquist S, Sjolander A, Hedenfalk I, Landberg G. Cyclin E overexpression obstructs infiltrative behavior in breast cancer: a novel role reflected in the growth pattern of medullary breast cancers. *Cancer Res* 2005; **65**: 9727–9734.
5. Boerner JL, Gibson MA, Fox EM, Posner ED, Parsons SJ, Silva CM, Shupnik MA. Estrogen negatively regulates epidermal growth factor (EGF)-mediated signal transducer and activator of transcription 5 signaling in human EGF family receptor-overexpressing breast cancer cells. *Mol Endocrinol* 2005; **19**: 2660–2670.
6. Burger AM, Gao YG, Amemiya Y, Kahn HJ, Kitching R, Yang YL, Sun P, Narod SA, Hanna WM, Seth AK. A novel RING-type ubiquitin ligase breast cancer-associated gene 2 correlates with outcome in invasive breast cancer. *Cancer Res* 2005; **65**: 10401–10412.
7. Cully M, Shiu J, Piekorz RP, Muller WJ, Done SJ, Mak TW. Transforming acidic coiled coil 1 promotes transformation and mammary tumorigenesis. *Cancer Res* 2005; **65**: 10363–10370.
8. Dabrosin C. Positive correlation between estradiol and vascular endothelial growth factor but not fibroblast growth factor-2 in normal human breast tissue in vivo. *Clin Cancer Res* 2005; **11**: 8036–8041.
9. Daosukho C, Ittarat W, Lin SM, Sawyer DB, Kiningham K, Lien YC, St Clair DK. Induction of manganese superoxide dismutase (MnSOD) mediates cardioprotective effect of tamoxifen (TAM). *J Mol Cell Cardiol* 2005; **39**: 792–803.
10. Demicco EG, Kavanagh KT, Romieu-Mourez R, Wang XB, Shin SR, Landesman-Bollag E, Seldin DC, Sonenshein GE. RelB/p52 NF-kappa B complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor I kappa B-alpha expression and promote carcinogenesis of the mammary gland. *Mol Cell Biol* 2005; **25**: 10136–10147.
11. Dietze EC, Bowie ML, Mrozek K, Caldwell LE, Neal C, Marjoram RJ, Troch MM, Bean GR, Yokoyama KK, Ibarra CA, Seewaldt VL. CREB-binding protein regulates apoptosis and growth of HMECs grown in reconstituted ECM via laminin-5. *J Cell Sci* 2005; **118**: 5005–5022.
12. Frank B, Hemminki K, Shanmugam KS, Meindl A, Klaes R, Schmutzler RK, Wappenschmidt B, Untch M, Bugert P, Bartram CR, Burwinkel B. Association of death receptor 4 haplotype 626C-683C with an increased breast cancer risk. *Carcinogenesis* 2005; **26**: 1975–1977.
13. Graham JD, Yager ML, Hill HD, Byth K, O'Neill GM, Clarke CL. Altered progesterone receptor isoform expression remodels progestin responsiveness of breast cancer cells. *Mol Endocrinol* 2005; **19**: 2713–2735.
14. Grainger DJ, Schofield PM. Tamoxifen for the prevention of myocardial infarction in humans: preclinical and early clinical evidence. *Circulation* 2005; **112**: 3018–3024.
15. Greendale GA, Palla SL, Ursin G, Laughlin GA, Crandall C, Pike MC, Reboussin BA. The association of endogenous sex steroids and sex steroid

First published online 22/03/06

BCO/551/2006/JW

- binding proteins with mammographic density: Results from the postmenopausal estrogen/progestin interventions mammographic density study. *Am J Epidemiol* 2005; **162**: 826–834.
16. Gyorffy B, Serra V, Jurchott K, Abdul-Ghani R, Garber M, Stein U, Petersen I, Lage H, Dietel M, Schafer R. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. *Oncogene* 2005; **24**: 7542–7551.
  17. Hodgson JG, Malek T, Bornstein S, Hariono S, Ginzinger DG, Muller WJ, Gray JW. Copy number aberrations in mouse breast tumors reveal loci and genes important in tumorigenic receptor tyrosine kinase signaling. *Cancer Res* 2005; **65**: 9695–9704.
  18. Howe LR, Chang SH, Tolle KC, Dillon R, Young LJT, Cardiff RD, Newman RA, Yang PY, Thaler HT, Muller WJ, Hudis C, Brown AMC, Hla T, Subbaramaiah K, Dannenberg AJ. HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. *Cancer Res* 2005; **65**: 10113–10119.
  19. Huang J, Li XD, Maguire CA, Hilf R, Bambara RA, Muyan M. Binding of estrogen receptor beta to estrogen response element in situ is independent of estradiol and impaired by its amino terminus. *Mol Endocrinol* 2005; **19**: 2696–2712.
  20. Jacquemier J, Padovani L, Rabayrol L, Lakhani SR, Penault-Llorca F, Denoux Y, Fiche M, Figueiro P, Maisongrosse V, Ledoussal V, Penuela JM, Udvarhely N, El Makdissi G, Ginestier C, Geneix J, Charafe-Jauffret E, Xerri L, Eisinger F, Birnbaum D, Sobol H, The European Working Group for Breast Screening Pathology, the Breast Cancer Linkage Consortium. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. *J Pathol* 2005; **207**: 260–268.
  21. Jirstrom K, Ryden L, Anagnostaki L, Nordenskjold B, Stal O, Thorstenson S, Chebil G, Jonsson PE, Ferno M, Landberg G. Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial. *J Clin Pathol* 2005; **58**: 1135–1142.
  22. Johnson KC. Accumulating evidence on passive and active smoking and breast cancer risk. *Int J Cancer* 2005; **117**: 619–628.
  23. Jung SS, Park HS, Lee IJ, Namkoong H, Shin SM, Cho GW, Ha SA, Park YG, Lee YS, Ko JS, Kim JW. The HCCR oncoprotein as a biomarker for human breast cancer. *Clin Cancer Res* 2005; **11**: 7700–7708.
  24. Kennedy RD, Gorski JJ, Quinn JE, Stewart GE, James CR, Moore S, Mulligan K, Emberley ED, Lioe TF, Morrison PJ, Mullan PB, Reid G, Johnston PG, Watson PH, Harkin DP. BRCA1 and c-Myc associate to transcriptionally repress psoriasis, a DNA damage-inducible gene. *Cancer Res* 2005; **65**: 10265–10272.
  25. Kim H, Chan R, Dankort DL, Zuo DM, Najoukas M, Park M, Muller WJ. The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation. *Oncogene* 2005; **24**: 7599–7607.
  26. Knowlden JM, Hutcheson IR, Barrow D, Gee JMW, Nicholson RI. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: A supporting role to the epidermal growth factor receptor. *Endocrinology* 2005; **146**: 4609–4618.
  27. Lagiou P, Samoli E, Lagiou A, Hsieh CC, Adami HO, Trichopoulos D. Maternal height, pregnancy estriol and birth weight in reference to breast cancer risk in Boston and Shanghai. *Int J Cancer* 2005; **117**: 494–498.
  28. Lee YR, Park J, Yu HN, Kim JS, Youn HJ, Jung SH. Up-regulation of P13K/Akt signaling by 17 beta-estradiol through activation of estrogen receptor-alpha but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells. *Biochem Biophys Res Commun* 2005; **336**: 1221–1226.
  29. Leo JCL, Wang SM, Guo CH, Aw SE, Zhao Y, Li JM, Hui KM, Lin VCL. Gene regulation profile reveals consistent anticancer properties of progesterone in Hormone-independent breast cancer cells transfected with progesterone receptor. *Int J Cancer* 2005; **117**: 561–568.
  30. Lester RD, Jo M, Campana WM, Gonias SL. Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. *J Biol Chem* 2005; **280**: 39273–39277.
  31. Lukong KE, Larocque D, Tyner AL, Richard S. Tyrosine phosphorylation of Sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression. *J Biol Chem* 2005; **280**: 38639–38647.
  32. Menendez JA, Vellon L, Colomer R, Lupu R. Effect of gamma-linolenic acid on the transcriptional activity of the Her-2/neu (erbB-2) oncogene. *J Natl Cancer Inst* 2005; **97**: 1611–1615.

33. Monzavi-Karbassi B, Whitehead TL, Jousheghany F, Artaud C, Hennings L, Shaaf S, Slaughter A, Korourian S, Kelly T, Blaszczyk-Thurin M, Kieber-Emmons T. Deficiency in surface expression of E-selectin ligand promotes lung colonization in a mouse model of breast cancer. *Int J Cancer* 2005; **117**: 398–408.
34. Prentice LM, Shadeo A, Lestou VS, Miller MA, DeLeeuw RJ, Makretsov N, Turbin D, Brown LA, Macpherson N, Yorida E, Cheang MCU, Bentley J, Chia S, O Nielsen T, Gilks CB, Lam W, Huntsman DG. NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. *Oncogene* 2005; **24**: 7281–7289.
35. Saitoh M, Ohmichi M, Takahashi K, Kawagoe J, Ohta T, Doshida M, Takahashi T, Igarashi H, Mori-Abe A, Du BT, Tsutsumi S, Kurachi H. Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-kappa B cascade in human breast cancer cells. *Endocrinology* 2005; **146**: 4917–4925.
36. Samuelson DJ, Aperavich BA, Haag JD, Gould NN. Fine mapping reveals multiple loci and a possible epistatic interaction within the mammary carcinoma susceptibility quantitative trait locus, Mcs5. *Cancer Res* 2005; **65**: 9637–9642.
37. Sartorius CA, Harvell DME, Shen TJ, Horwitz KB. Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth. *Cancer Res* 2005; **65**: 9779–9788.
38. Sentis S, Le Romancer M, Bianchin C, Rostan MC, Corbo L. Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. *Mol Endocrinol* 2005; **19**: 2671–2684.
39. Shetty A, Loddo M, Fanshawe T, Prevost AT, Sainsbury R, Williams GH, Stoeber K. DNA replication licensing and cell cycle kinetics of normal and neoplastic breast. *Br J Cancer* 2005; **93**: 1295–1300.
40. Singh RR, Barnes CJ, Talukder AH, Fuqua SAW, Kumar R. Negative regulation of estrogen receptor alpha transactivation functions by LIM domain only 4 protein. *Cancer Res* 2005; **65**: 10594–10601.
41. Suzuki R, Ye WM, Rylander-Rudqvist T, Saji S, Colditz GA, Wolk A. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: A prospective cohort study. *J Natl Cancer Inst* 2005; **97**: 1601–1608.
42. Tari AM, Simeone AM, Li YJ, Gutierrez-Puente Y, Lai SL, Symmans WF. Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl) retinamide inhibitory effects in breast cancer cells. *Lab Invest* 2005; **85**: 1357–1367.
43. Taverna D, Crowley D, Connolly M, Bronson RT, Hynes RO. A direct test of potential roles for beta 3 and beta 5 integrins in growth and metastasis of murine mammary carcinomas. *Cancer Res* 2005; **65**: 10324–10329.
44. Tian KG, Jurukovski V, Wang XP, Kaplan MH, Xu HP. Epigenetic regulation of WTH3 in primary and cultured drug-resistant breast cancer cells. *Cancer Res* 2005; **65**: 10024–10031.
45. Van den Eynden GG, Van der Auwera I, Van Laere SJ, Colpaert CG, Turley H, Harris AL, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA. Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer. *Br J Cancer* 2005; **93**: 1128–1136.
46. Van der Auwera I, Van den Eynden GG, Colpaert CG, Van Laere SJ, van Dam P, Van Marck EA, Dirix LY, Vermeulen PB. Tumor lymphangiogenesis in inflammatory breast carcinoma: A histomorphometric study. *Clin Cancer Res* 2005; **11**: 7637–7642.
47. Wang L, Devarajan E, He J, Sekhar PRY, Le Dai J. Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression. *Cancer Res* 2005; **65**: 10289–10297.
48. Wang TL, Tamae D, LeBon T, Shively JE, Yen Y, Li JJ. The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells. *Cancer Res* 2005; **65**: 10338–10346.
49. Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U, Rau T, Sauter G, Heukeshoven J, Pantel K. Changes in cytoskeletal protein composition indicative of an epithelial–mesenchymal transition in human micrometastatic and primary breast carcinoma cells. *Clin Cancer Res* 2005; **11**: 8006–8014.
50. Wirtenberger M, Hemminki K, Forsti A, Klaes R, Schmutzler RK, Grzybowska E, Bermejo JL, Wappenschmidt B, Bugert P, Butkiewicz D, Pamula J, Pekala W, Zientek H, Bartram CR, Burwinkel B. C-MYC Asn11Ser is associated with increased risk for familial

- breast cancer. *Int J Cancer* 2005; **117**: 638–642.
51. Wu LC, Tannock IF. Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy. *Clin Cancer Res* 2005; **11**: 8195–8200.
52. Yang XH, Liu DH, Murray TJ, Mitchell GC, Hesterman EV, Karchner SI, Merson RR, Hahn ME, Sherr DH. The aryl hydrocarbon receptor constitutively represses c-myc transcription in human mammary tumor cell. *Oncogene* 2005; **24**: 7869–7881.
53. Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, Toker A. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. *Mol Cell* 2005; **20**: 539–550.

*Prepared by  
R. Sutherland, J. Scorer  
Cancer Research Program  
Garvan Institute of Medical Research  
Darlinghurst, NSW, Australia*